Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-07-31

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic steatosis. In order to enroll subject groups with varying degrees of risk, the study has included multiple cohorts (Cohorts A-G). Additions and removal of cohorts has been accomplished with protocol amendments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects

NCT00707746

Metabolic Diseases Hyperlipidemias Metabolic Disorder +3 more

COMPLETED PHASE2

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

NCT00281008

Hypercholesterolemia, Familial

COMPLETED PHASE2

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

NCT00694109

Lipid Metabolism, Inborn Errors Hypercholesterolemia, Autosomal Dominant Hyperlipidemias +11 more

COMPLETED PHASE3

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

NCT00477594

Lipid Metabolism, Inborn Errors Hypercholesterolemia, Autosomal Dominant Hyperlipidemias +11 more

COMPLETED PHASE2

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

NCT01475825

Hypercholesterolemia Heterozygous Familial

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a randomized, double-blind, placebo-controlled study to measure the effect of treatment with mipomersen on liver triglyceride (TG) content in patients with varying degrees of hyperlipidemia and risk for hepatic steatosis.

The original study design included 4 cohorts (Cohorts A through D). Subsequent protocol amendments added 3 cohorts (Cohorts E, F, and G) to the study, truncated the enrollment of Cohort D, and eliminated Cohorts B and C. The study consisted of up to a 3-week screening period; a 4-week (Cohorts A and D), 13-week (Cohort E), or 52-week (Cohort G) treatment period; and a 20-week post-treatment follow-up period. Cohort F was an observational cohort, and therefore, was not treated with study drug. Patients in this cohort underwent a 15-week Magnetic resonance spectroscopy (MRS) and ultrasound evaluation period.

The study cohorts are:

Cohort A: Healthy volunteers with LDL-C \<140 mg/dL (3.6 mmol/L), serum TG \<200 mg/dL (2.3 mmol/L), hemoglobin A1c (HbA1c) \<6.0%, and hepatic TG content \<5% (as measured by MRS at screening). Patients were randomized to mipomersen 200 mg or placebo and treated for 4 weeks.

Cohorts B+C were eliminated in a protocol amendment prior to enrolling any patients and are not discussed further.

Cohort D: In an amendment to the protocol, Cohort D was closed to enrollment. One patient had already been enrolled in the study prior to the amendment. The patient enrolled in this cohort had impaired fasting glucose (defined as fasting blood glucose \>6 mmol/L and \<7 mmol/L) and mixed dyslipidemia (LDL-C \<215 mg/dL \[5.6 mmol/L\] and serum TG \>200 mg/dL \[2.3 mmol/L\]). The patient was treated with mipomersen 200 mg for 4 weeks.

Cohort E: Patients with uncomplicated heterozygous familial hypercholesterolemia (HeFH) (Alanine aminotransferase (ALT) ≤1.5 \* upper limit of normal Upper limit of normal (ULN), no evidence of insulin resistance or metabolic syndrome, and hepatic TG content \<5% by MRS at screening). Patients were to remain on their baseline statin ± ezetimibe regimen but were to wash out from other lipid-lowering agents (e.g., fenofibrate, non-dietary omega-3 fatty acids, and niacin) at least 8 weeks prior to the MRS at screening. Patients were randomized to either mipomersen 200 mg or placebo for 13 weeks.

Cohort F: Patients with familial hypobetalipoproteinemia (FHBL) (a documented APOB gene mutation that results in the expression of a truncated form of apo B). Patients in this cohort were evaluated by MRS, ultrasound, and laboratory tests; however, they were not treated with mipomersen or placebo.

Cohort G: Patients with well-controlled type 2 diabetes mellitus (HbA1c ≤8.0%), hypercholesterolemia (LDL-C \>100 mg/dL (2.59 mmol/L), and normal serum TG levels (≤200 mg/dL \[2.26 mmol/L\]). Patients were to have been on a stable dose of antidiabetic and lipid-lowering medications \>3 months prior to screening and were expected to remain stable for the duration of the study. Patients were randomized to either mipomersen 200 mg or placebo for 26 weeks, followed by 26 additional weeks of mipomersen 200 mg. Recruiting difficulties caused this cohort to close early.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lipid Metabolism, Inborn Errors Hyperlipidemias Metabolic Diseases Hypolipoproteinemia Hypolipoproteinemias Hypobetalipoproteinemias Metabolism, Inborn Errors Genetic Diseases, Inborn Infant, Newborn, Diseases Congenital Abnormalities Metabolic Disorder Hypercholesterolemia Dyslipidemias Lipid Metabolism Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort A: mipomersen

Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.

Group Type EXPERIMENTAL

mipomersen

Intervention Type DRUG

200 mg subcutaneous injections

Cohort A: placebo

Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

subcutaneous injections

Cohort D: mipomersen

Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.

Group Type EXPERIMENTAL

mipomersen

Intervention Type DRUG

200 mg subcutaneous injections

Cohort D: placebo

Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

subcutaneous injections

Cohort E: mipomersen

Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.

Group Type EXPERIMENTAL

mipomersen

Intervention Type DRUG

200 mg subcutaneous injections

Cohort E: placebo

Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

subcutaneous injections

Cohort F: no intervention

A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.

Group Type NO_INTERVENTION

No interventions assigned to this group

Cohort G: mipomersen

Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.

Group Type EXPERIMENTAL

mipomersen

Intervention Type DRUG

200 mg subcutaneous injections

Cohort G: placebo followed by mipomersen

Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.

Group Type PLACEBO_COMPARATOR

mipomersen

Intervention Type DRUG

200 mg subcutaneous injections

Placebo

Intervention Type DRUG

subcutaneous injections

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mipomersen

200 mg subcutaneous injections

Intervention Type DRUG

Placebo

subcutaneous injections

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ISIS 301012 mipomersen sodium Kynamro™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Group A - are healthy subjects
* Group D - has impaired fasting glucose and mixed dyslipidemia
* Group E - has a diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH) and on stable lipid-lowering therapy for 3 months
* Group F - has a diagnosis of Familial Hypobetalipoproteinemia (FHBL)
* Group G - has a diagnosis of Diabetes and hypercholesterolemia

Exclusion Criteria

* Medical, surgical, laboratory or other conditions which in the judgment of the Physician Investigator would make the subject unsuitable for enrollment, or potentially interfere with subject participation or completion of the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes